Tom 12, Nr 3 (2017)
UCZYMY SIĘ!
Opublikowany online: 2017-08-02
Wyświetlenia strony
646
Wyświetlenia/pobrania artykułu
3151
Pacjent z chorobą nowotworową i ostrym zespołem wieńcowym
Kardiol Inwazyjna 2017;12(3):16-23.
Streszczenie
Współwystępowanie chorób nowotworowych i chorób sercowo-naczyniowych dotyczy około 1,9–4,2% pacjentów z tymi schorzeniami. Ze względu na stały wzrost występowania obu tych chorób, aktualna wiedza z zakresu kardioonkologii jest powszechnie oczekiwana. W niniejszym opracowaniu zostały przedstawione wybrane zagadnienia dotyczące tego tematu, w tym mechanizmy ostrych zespołów wieńcowych (OZW) spowodowanych chorobą nowotworową, a także mechanizmy toksycznego wpływu chemioterapii i radioterapii na układ sercowo-naczyniowy, zwłaszcza na tętnice wieńcowe i ich związek z OZW u pacjentów poddawanych takiemu leczeniu. Przedstawiono również problem powikłań krwotocznych lub niedokrwistości indukowanej lekami przeciwpłytkowymi lub przeciwzakrzepowymi po OZW związanych z chorobą nowotworową. Na końcu zostały zamieszczone wskazówki dotyczące postępowania z pacjentem z powikłaniem krwotocznym lub niedokrwistością z powodu choroby nowotworowej i OZW.
Słowa kluczowe: choroba nowotworowaostry zespół wieńcowykardioonkologia
Referencje
- Vicinelli P, Martinoni A, Villani C, et al. Acute coronary syndrome and cancer: which therapeutic option first? G Ital Cardiol (Rome). 2015; 16(5): 316–319.
- Blaes A, Prizment A, Koene RJ, et al. Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease. Heart Fail Clin. 2017; 13(2): 367–380.
- Waller B, Fry E, Hermiller J, et al. Nonatherosclerotic causes of coronary artery narrowing-Part III. Clinical Cardiology. 1996; 19(8): 656–661.
- Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res. 2013; 131: S59–S62.
- Jachmann-Jahn U, Cornely OA, Laufs U, et al. Acute anterior myocardial infarction as first manifestation of acute myeloid leukemia. Ann Hematol. 2001; 80(11): 677–681.
- Xiong N, Gao W, Pan J, et al. Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review. J Thromb Thrombolysis. 2017; 44(1): 57–62.
- Yu R, Nissen NN, Bannykh SI. Cardiac complications as initial manifestation of pheochromocytoma: frequency, outcome, and predictors. Endocr Pract. 2012; 18(4): 483–492.
- Uriarte DS, Lucreziotti S, Sponzilli C, et al. Acute myocardial infarction as first manifestation of left atrial myxoma in a young woman: role of echocardiography. J Cardiovasc Med (Hagerstown). 2015; 16 Suppl 2: S69–S70.
- Konstanty-Kalandyk J, Wierzbicki K, Bartuś K, et al. Acute myocardial infarction due to coronary embolisation as the first manifestation of left atrial myxoma. Kardiol Pol. 2013; 71(4): 403–405.
- Zamorano J, Lancellotti P, Muñoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal. 2016; 37(36): 2768–2801.
- Iliescu CA, Grines CL, Herrmann J, et al. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc Interv. 2016; 87(5): E202–E223.
- Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008; 134(1): 75–82.
- Rao AS, Kumar R, Narayanan GS. A rare case of cisplatin-induced acute myocardial infarction in a patient receiving chemoradiation for lung cancer. J Cancer Res Ther. 2015; 11(4): 983–985.
- Jang S, Zheng C, Tsai HT, et al. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer. 2016; 122(1): 124–130.
- Schrader C, Keussen C, Bewig B, et al. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005; 10(11): 498–501.
- Lynch DR, Kickler TS, Rade JJ. Recurrent myocardial infarction associated with gefitinib therapy. J Thromb Thrombolysis. 2011; 32(1): 120–124.
- Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016; 6: e384.
- Lee KH, Lee JS, Kim SH. Electrocardiographic changes simulating acute myocardial infarction or ischemia associated with combination chemotherapy with etoposide, cisplatin, and 5-fluorouracil. Korean J Intern Med. 1990; 5(2): 112–117.
- McEniery PT, Dorosti K, Schiavone WA, et al. Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol. 1987; 60(13): 1020–1024.
- Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002; 9(2 Suppl): 36–44.
- Jin Kim Y, Hyun Kim C, Hwan Cheong J, et al. Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas. Tumori. 2011; 97(5): 639–646.
- Yao RX, He MQ, He MQ, et al. Vascular Endothelial Growth Factor and Cluster of Differentiation 34 for Assessment of Perioperative Bleeding Risk in Gastric Cancer Patients. Chin Med J. 2016; 129(16): 1950.
- Fu H, Vadalia N, Xue ER, et al. Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study. J Hematol Oncol. 2017; 10(1): 74.
- Wei H, Shang J, Keohane C, et al. A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/+) mice. Thromb Haemost. 2014; 111(6): 1121–1132.
- Roe MT, Cyr DD, Eckart D, et al. TRILOGY ACS Investigators. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J. 2016; 37(4): 412–422.
- Asiimwe A, Li JJ, Weerakkody G, et al. Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin. Curr Drug Saf. 2013; 8(4): 261–269.
- Desai J, Granger CB, Weitz JI, et al. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc. 2013; 78(2): 227–239.
- Yasuta S, Yamauchi J, Satoh A, et al. Synchronous Triple Malignant Tumors (Hilar Cholangiocarcinoma, Ascending Colon Cancer, Liposarcoma) Resected in a Two-Stage Procedure--A Case Report. Gan To Kagaku Ryoho. 2015; 42(12): 1752–1754.
- Kaltenbach T, Cabral P, Yee L, et al. Giant small-bowel GI stromal tumor: aspirin provocation to endoscopically unmask site of obscure overt GI bleeding. Gastrointest Endosc. 2008; 68(5): 1026.
- Moschini M, Karnes RJ, Suardi N, et al. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clin Genitourin Cancer. 2016; 14(3): e245–e250.
- Diehl C, Haux D, Sahm F, et al. Intracranial tumour haemorrhage following intravenous thrombolysis. J Clin Neurosci. 2016; 26: 145–146.
- Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011; 38(3): 259–260.
- Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012; 5(2): 261–269.
- Kwak YL, Kim JC, Choi YS, et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol. 2010; 56(24): 1994–2002.
- Leibovitz A, Baumoehl Y, Walach N, et al. Medical staff attitudes: views and positions regarding blood transfusion to terminally ill cancer patients. Am J Clin Oncol. 2004; 27(5): 542–546.
